3-(3-Butylamino-2-hydroxy-propoxy)-1-hydroxy-xanthen-9-one acts as a topoisomerase IIα catalytic inhibitor with low DNA damage

European Journal of Medicinal Chemistry

Volumn 69, Issue , 2013, Pages 139-145

  Park, So Eun ^a   Chang, In Hye ^b   Jun, Kyu Yeon ^a   Lee, Eunyoung ^a   Lee, Eung Seok ^c   Na, Younghwa ^d   Kwon, Youngjoo ^a  

^a Ewha Womans University   (South Korea)

^b Catholic University of Daegu   (South Korea)

^c Yeungnam University   (South Korea)

^d CHA University   (South Korea)

Author keywords

Anticancer agents; ATP competitive inhibitor; DNA intercalator; Topoisomerase II catalytic inhibitor; Xanthones

Indexed keywords

1 HYDROXY 3 (2' HYDROXY 3 (BUTYLAMINO)PROPOXY)XANTHONE; 1 HYDROXY 3 (2' HYDROXY 3' (AMYLAMINO)PROPOXY)XANTHONE; 1 HYDROXY 3 (2' HYDROXY 3' (HEXYLAMINO)PROPOXY)XANTHONE; 1 HYDROXY 3 (2' HYDROXY 3' (PROPYLAMINO)PROPOXY) XANTHONE; 1 HYDROXY 5 METHOXY 3 (2' HYDROXY 3' (AMYLAMINO) PROPOXY)XANTHONE; 1 HYDROXY 5 METHOXY 3 (2' HYDROXY 3' (BUTYLAMINO) PROPOXY)XANTHONE; 1 HYDROXY 5 METHOXY 3 (2' HYDROXY 3' (HEXYLAMINO) PROPOXY)XANTHONE; 1 HYDROXY 5 METHOXY 3 (2' HYDROXY 3' (PROPYLAMINO) PROPOXY)XANTHONE; ADENOSINE TRIPHOSPHATASE; ADENOSINE TRIPHOSPHATE; ALIPHATIC AMINE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CARBON; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; ETOPOSIDE; UNCLASSIFIED DRUG; XANTHONE DERIVATIVE;

ARTICLE; BINDING SITE; CANCER CELL CULTURE; COLORECTAL CARCINOMA; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; DOUBLE STRANDED DNA BREAK; DRUG MECHANISM; DRUG SCREENING; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HYDROLYSIS;

ANTICANCER AGENTS; ATP-COMPETITIVE INHIBITOR; DNA INTERCALATOR; TOPOISOMERASE IIΑ CATALYTIC INHIBITOR; XANTHONES;

ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; BIOCATALYSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DNA DAMAGE; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; STRUCTURE-ACTIVITY RELATIONSHIP; TOPOISOMERASE II INHIBITORS; XANTHONES;

EID: 84883511339     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2013.07.048     Document Type: Article

References (27)

1. J.J. Champoux DNA topoisomerases: structure, function, and mechanism Annu. Rev. Biochem. 70 2001 369 413 (Pubitemid 32662215)
2. K.D. Corbett, and J.M. Berger Structure, molecular mechanisms, and evolutionary relationships in DNA topoisomerases Annu. Rev. Biophys. Biomol. Struct. 33 2001 95 118
3. J.L. Nitiss Targeting DNA topoisomerase II in cancer chemotherapy Nat. Rev. Cancer 9 2009 338 350
4. J.L. Nitiss DNA topoisomerase II and its growing repertoire of biological functions Nat. Rev. Cancer 9 2009 327 337
5. Y. Pommier, E. Leo, H. Zhang, and C. Marchand DNA topoisomerases and their poisoning by anticancer and antibacterial drugs Chem. Biol. 17 2010 421 433
6. F. Cortés, N. Pastor, S. Mateos, and I. Domínguez Roles of DNA topoisomerases in chromosome segregation and mitosis Mutat. Res. 543 2003 59 66 (Pubitemid 36050912)
7. K. Villman, E. Ståhl, G. Liljegren, U. Tidefelt, and M.G. Karlsson Topoisomerase II-alpha expression in different cell cycle phases in fresh human breast carcinomas Mod. Pathol. 15 2002 486 491 (Pubitemid 34521397)
8. J. Wang, B. Xu, P. Yuan, P. Zhang, Q. Li, F. Ma, and Y. Fan TOP2A amplification in breast cancer is a predictive marker of anthracycline-based neoadjuvant chemotherapy efficacy Breast Cancer Res. Treat. 135 2012 531 537
9. J.A. Sparano, L.J. Goldstein, N.E. Davidson, G.W. Sledge Jr., and R. Gray TOP2A RNA expression and recurrence in estrogen receptor-positive breast cancer Breast Cancer Res. Treat. 134 2012 751 757
10. Y. Hong, M. Sang, C. Shang, Y.X. Xue, and Y.H. Liu Quantitative analysis of topoisomerase II alpha and evaluation of its effects on cell proliferation and apoptosis in glioblastoma cancer stem cells Neurosci. Lett. 518 2012 138 143
11. A.M. Wilstermann, and N. Osheroff Substituents on etoposide that interact with human topoisomerase IIα in the binary enzyme-drug complex: contributions to etoposide binding and activity Curr. Top. Med. Chem. 3 2003 321 338
12. E. Toyoda, S. Kagaya, I.G. Cowell, A. Kurosawa, K. Kamoshita, K. Nishikawa, S. Iiizumi, H. Koyama, C.A. Austin, and N. Adachi NK314, a topoisomerase II inhibitor that specifically targets the alpha isoform Biol. Chem. 283 2008 23711 23720
13. C.C. Wu, T.K. Li, L. Farh, L.Y. Lin, T.S. Lin, Y.J. Yu, T.J. Yen, C.W. Chiang, and N.L. Chan Structural basis of type II topoisomerase inhibition by the anticancer drug etoposide Science 333 2011 459 462
14. K.Y. Jun, E. Lee, M.J. Jung, O.H. Lee, E.S. Lee, H.Y. Park Choo, Y. Na, and Y. Kwon Synthesis, biological evaluation, and molecular docking study of 3-(3′-heteroatom substituted-2′-hydroxy-1′-propyloxy) xanthone analogues as novel topoisomerase IIα catalytic inhibitor Eur. J. Med. Chem. 46 2011 1964 1971
15. A.K. Larsen, A.E. Escargueil, and A. Skladanowski Catalytic topoisomerase II inhibitors in cancer therapy Pharmacol. Ther. 99 2003 67 81
16. N.A. Gormley, G. Orphanides, A. Meyer, P.M. Cullis, and A. Maxwell The interaction of coumarin antibiotics with fragments of DNA gyrase B protein Biochemistry 35 1996 5083 5092 (Pubitemid 26126725)
17. G. Dougherty The unwinding of circular DNA by intercalating agents as determined by gel electrophoresis Biosci. Rep. 3 1983 453 460 (Pubitemid 13036536)
18. A.T. Baviskar, C. Madaan, R. Preet, P. Mohapatra, V. Jain, A. Agarwal, S.K. Guchhait, C.N. Kundu, U.C. Banerjee, and P.V. Bharatam N-Fused imidazoles as novel anticancer agents that inhibit catalytic activity of topoisomerase IIα and induce apoptosis in G1/S phase J. Med. Chem. 54 2011 5013 5030
19. B.A.D. Neto, and A.A.M. Lapis Recent developments in the chemistry of deoxyribonucleic acid (DNA) intercalators: principles, design, synthesis, applications and trends Molecules 14 2009 1725 1746
20. J.R. Vance, and K.F. Bastow Inhibition of DNA topoisomerase II catalytic activity by the antiviral agents 7-chloro-1,3-dihydroxyacridone and 1,3,7-trihydroxyacridone Biochem. Pharmacol. 58 1999 703 708 (Pubitemid 29296892)
21. S.J. Froelich-Ammon, and N. Osheroff Topoisomerase poisons: harnessing the dark side of enzyme mechanism J. Biol. Chem. 270 1995 21429 21432
22. K. Kang, H.J. Lee, C.Y. Kim, S.B. Lee, S.H. Jung, K.H. Cha, W.D. Park, Y.C. Sohn, and C.W. Nho Tectoridin, a poor ligand of estrogen receptor α, exerts its estrogenic effects via an ERK-dependent pathway Mol. Cells 27 2009 351 357
23. S.I. Kim, S.H. Lee, E.S. Lee, C.S. Lee, and Y. Jahng New topoisomerases inhibitors: synthesis of rutaecarpine derivatives and their inhibitory activity against topoisomerases Arch. Pharm. Res. 35 2012 785 789
24. R. Karki, P. Thapa, H.Y. Yoo, T.M. Kadayat, P.H. Park, Y. Na, E. Lee, K.H. Jeon, W.J. Cho, H. Choi, Y. Kwon, and E.S. Lee Dihydroxylated 2,4,6-triphenyl pyridines: synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study Eur. J. Med. Chem. 49 2012 219 228
25. H.E. Han, T.K. Kim, H.J. Son, W.J. Park, and P.L. Han Activation of autophagy pathway suppresses the expression of iNOS, IL6 and cell death of LPS-stimulated microglia cells Biomolecules Ther. 21 2013 21 28
26. P. Chène, J. Rudloff, J. Schoepfer, P. Furet, P. Meier, Z. Qian, J.M. Schlaeppi, R. Schmitz, and T. Radimerski Catalytic inhibition of topoisomerase II by a novel rationally designed ATP-competitive purine analogue BMC Chem. Biol. 9 2009 1 16
27. R.R. Tice, E. Agurell, D. Anderson, B. Burlinson, A. Hartmann, H. Kobayashi, H. Kobayashi, Y. Miyamae, E. Rojas, J.C. Ryu, and Y.F. Sasaki Single cell gel/comet assay: guidelines for in vitro and in vivo genetic toxicology testing Environ. Mol. Mutagen. 35 2000 206 221 (Pubitemid 30196665)